News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
Combination therapy, in which doctors prescribe more than one drug to treat type 2 diabetes, is a fairly common practice. However, most newly diagnosed type 2 patients start off with metformin or a sulfonylurea and don't go on a two-drug therapy until their first drug begins to lose its effectiveness. But combination therapy could soon become an earlier option for people with type 2.
A Danish study of 107,806 adults taking various diabetes medications has found that three drugs are the most effective at lowering the risk of cardiovascular disease and death: metformin, gliclazide (not marketed in the US), and repaglinide (Prandin). Other common diabetes medications, including glimepiride, glibenclamide (glyburide), glipizide, and tolbutamide, were linked to a higher risk of death both from all causes and from heart attack and stroke.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health.
Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.